ArticleJAC-antimicrobial resistance2021
Opportunities to enhance antibiotic stewardship: colistin use and outcomes in a low-resource setting.
Article in JAC-antimicrobial resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of colistin resistance in clinicalFuture microbiology · 2025Pooled it
- Colistin Resistance in Klebsiella pneumoniae: Mechanisms, Detection, and Clinical Impact.Cureus · 2026Review
- Epidemiology and predictors of multidrug-resistant Enterobacteriaceae in intensive care units of a tertiary hospital in Somalia: a five-year retrospective study (2019-2024).Frontiers in antibiotics · 2026Article
- Prevalence, Appropriateness, and Outcomes of Colistin Use in Multidrug-ResistantMedicina (Kaunas, Lithuania) · 2025Article
- Pre- and Post-COVID-19 Antibiotic Consumption and Stewardship Program in a Southern Italian Hospital.Antibiotics (Basel, Switzerland) · 2024Article
- The impact of colistin-based regimens on mortality compared to other antimicrobials in patients with carbapenem-resistant Enterobacterales bacteremia in South African hospitals: a cross-sectional study.BMC infectious diseases · 2024Article
- Ongoing Efforts to Improve Antimicrobial Utilization in Hospitals among African Countries and Implications for the Future.Antibiotics (Basel, Switzerland) · 2022Article
- Antibiotic Use and Stewardship Indicators in the First- and Second-Level Hospitals in Zambia: Findings and Implications for the Future.Antibiotics (Basel, Switzerland) · 2022Article
- Plazomicin in multidrug-resistant complicated urinary tract infections: a scoping review.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColistin use is increasing with the rise in MDR Gram-negative infections globally. Effective antibiotic stewardship is essential to preserve this antibiotic of last resort.
objectivesThis study investigated stewardship and safety errors related to colistin use to identify opportunities for improvement. PATIENTS AND
methodsA prospective descriptive study involving all patients 13 years and older treated with colistin at a tertiary hospital in Cape Town, South Africa, between August 2018 and June 2019. We collected clinical, laboratory and outcome data and assessed provided treatment for stewardship and safety errors.
resultsWe included 44 patients. Treatment errors were identified for 34 (77%) patients (median = 1), most commonly inadequate monitoring of renal function (
conclusionsThis study has identified opportunities to enhance colistin stewardship and improve efficacy and safety of prescription. The appearance of colistin-resistant organisms reinforces the urgent need to ensure effective and appropriate use of colistin.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.